Here, we hypothesized that differences in RyR2 activity (i.e., due to a CPVT mutation) determine the potency of open-state RyR2 blockers such as FLEC against Ca2+ waves in cardiomyocytes. Here, RYR2 is linked to catecholaminergic polymorphic ventricular tachycardia.